[ad_1]
Only one month into his CEO tenure at ADC Therapeutics, Ameet Mallik is bringing in new individuals to assemble his prime crew.
David Gilman, a seasoned biopharma advisor who held a quick stint scouting offers for Novartis’ oncology group, is becoming a member of the Swiss biotech as chief enterprise and technique officer.
A veteran of Novartis himself, Mallik jumped to ADC final month after his first CEO expertise at Rafael Holdings imploded, changing Chris Martin, the long-time chief who’d been concerned with the corporate since its formation in 2011 and oversaw a slate of financings, offers, an IPO and an FDA approval.
Maintain studying Endpoints with a free subscription
Unlock this story immediately and be part of 143,700+ biopharma professionals studying Endpoints each day — and it is free.
[ad_2]
Supply hyperlink